Securities Report - 111th Fiscal Period (2025/04/01 - 2026/03/31)

Terumo Corporation Securities Report - 111th Fiscal Period (2025/04/01 - 2026/03/31)

This report is the securities report submitted by Terumo Corporation (hereinafter referred to as "the Company") pursuant to the Financial Instruments and Exchange Act, covering business performance, financial condition, management policies, and other significant matters for the 111th fiscal period (April 1, 2025 to March 31, 2026).

Since its founding in 1921, the Company has been committed to contributing to human health through the manufacturing and sale of thermometers. Over time, it has expanded into developing and providing high-value-added medical devices such as blood transfusion equipment, cardiovascular treatment devices, and diabetes-related products. Today, Terumo operates in over 80 countries worldwide, growing into a global healthcare enterprise.

The Company's business is primarily divided into the following three segments:

- Medical Segment: Medical devices used for diagnosis and treatment, including thermometers, blood pressure monitors, catheters, and intravascular therapy devices - Life Science Segment: Equipment and consumables for cell therapy and regenerative medicine - Diabetic Care Segment: Products supporting the lives of diabetes patients, including blood glucose meters, insulin pumps, and diabetes management software

Regarding the business environment for the 111th fiscal period, demand for medical devices is expected to remain strong, driven by global aging and increasing emphasis on preventive and home-based healthcare. However, risks such as healthcare cost containment policies in various countries, foreign exchange fluctuations, and supply chain instability persist.

To respond to these environmental changes, the Company will continue its commitment to sustained investment in research and development, while pursuing strategic expansion into emerging markets, advancing into the digital health sector, and promoting ESG management to achieve sustainable growth.

In terms of financial condition, the Company maintains a stable revenue base and sound financial structure, with an equity ratio of over 35%. Regarding shareholder returns, the Company will continue stable dividend payments and consider share buybacks.

Going forward, based on the management philosophy of 'Quality First,' the Company will strive to achieve both social and corporate value by providing products and services that meet the trust of patients and healthcare professionals.